In the wake of the nomination of Kathi Vidal as Director of the USPTO, there will be significant attention paid to the agency’s responses to calls from both the executive and legislative branches to remake the agency’s...more
10/27/2021
/ Biden Administration ,
Biosimilars ,
Biotechnology ,
Competition ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Healthcare Reform ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Patent Applications ,
Patent Ownership ,
Patient Access ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Post-Grant Review ,
Prescription Drugs ,
Regulatory Agenda ,
USPTO